116 related articles for article (PubMed ID: 4150936)
1. Some benzhydryl derivatives as central dopamine receptor stimulating agents.
van Beek MC; Timmerman H
J Pharm Pharmacol; 1974 Jan; 26(1):57-8. PubMed ID: 4150936
[No Abstract] [Full Text] [Related]
2. Dopaminergic nature of apomorphine-induced pecking in pigeons.
Cheng HC; Long JP
Eur J Pharmacol; 1974 May; 26(2):313-20. PubMed ID: 4851427
[No Abstract] [Full Text] [Related]
3. Apomorphine induced biting and fighting behaviour in reserpinized rats and an approach to the mechanism of action.
Patni SK; Dandiya PC
Life Sci; 1974 Feb; 14(4):737-45. PubMed ID: 4856759
[No Abstract] [Full Text] [Related]
4. Effect of apomorphine on motility in rats.
Maj J; Grabowska M; Gajda L
Eur J Pharmacol; 1972 Feb; 17(2):208-14. PubMed ID: 5026397
[No Abstract] [Full Text] [Related]
5. Alpha-methyldopamine derivatives. Synthesis and pharmacology.
Borgman RJ; Baylor MR; McPhillips JJ; Stitzel RE
J Med Chem; 1974 Apr; 17(4):427-30. PubMed ID: 4830540
[No Abstract] [Full Text] [Related]
6. Dopamine receptor in the reward system of the rat.
Kadzielawa K
Arch Int Pharmacodyn Ther; 1974 Jun; 209(2):214-26. PubMed ID: 4441165
[No Abstract] [Full Text] [Related]
7. Modification of striatal acetylcholine concentration by dopamine receptor agonists and antagonists.
Sethy VH; VAN Woert MH
Res Commun Chem Pathol Pharmacol; 1974 May; 8(1):13-28. PubMed ID: 4847901
[No Abstract] [Full Text] [Related]
8. Functional role of the nigro-neostriatal dopamine neurons.
Andén NE; Dahlström A; Fuxe K; Larsson K
Acta Pharmacol Toxicol (Copenh); 1966; 24(2):263-74. PubMed ID: 5297995
[No Abstract] [Full Text] [Related]
9. Modification of the tremorigenic activity of physostigmine.
Ambrani LM; Van Woert MH
Br J Pharmacol; 1972 Oct; 46(2):344-7. PubMed ID: 4651776
[TBL] [Abstract][Full Text] [Related]
10. Increase of striatal dopamine turnover by drugs: interference with granular storage or receptor blackade?
Saner A; Pletscher A
Eur J Pharmacol; 1977 Mar; 42(2):155-60. PubMed ID: 844496
[TBL] [Abstract][Full Text] [Related]
11. Actions of levodopa and dopamine in the central nervous system.
Sourkes TL
JAMA; 1971 Dec; 218(13):1909-11. PubMed ID: 4398939
[No Abstract] [Full Text] [Related]
12. [Effect of catecholamines on the central nervous system. (1). Role of dopamine in the brain in animal behavioral changes].
Kameyama T; Kisara K
Nihon Yakurigaku Zasshi; 1966 Sep; 62(5):317-26. PubMed ID: 5298294
[No Abstract] [Full Text] [Related]
13. Dopa reversal of reserpine enhancement of audiogenic seizure susceptibility in mice.
Boggan WO; Seiden LS
Physiol Behav; 1971 Mar; 6(3):215-7. PubMed ID: 5125476
[No Abstract] [Full Text] [Related]
14. A model for the quantitative study of central dopaminergic and serotoninergic activity.
Bieger D; Larochelle L; Hornykiewicz O
Eur J Pharmacol; 1972 Apr; 18(1):128-36. PubMed ID: 4555562
[No Abstract] [Full Text] [Related]
15. Rapid and dissociated changes in sensitivities of different dopamine receptors in mouse brain.
Costentin J; Protais P; Schwartz JC
Nature; 1975 Oct; 257(5525):405-7. PubMed ID: 170532
[No Abstract] [Full Text] [Related]
16. Potentiation of effects of L-dopa on conditioned avoidance behavior by inhibition of extracerebral dopa decarboxylase.
Seiden LS; Martin TW
Physiol Behav; 1971 Apr; 6(4):453-8. PubMed ID: 5148757
[No Abstract] [Full Text] [Related]
17. Behavior and biochemical effects of preferentially protecting monoamines in the brain against the action of reserpine.
Butcher LL; Rhodes DL; Yuwiler A
Eur J Pharmacol; 1972 May; 18(2):204-12. PubMed ID: 4537669
[No Abstract] [Full Text] [Related]
18. [Compounds stimulating central catecholamine receptors].
Grabowska M
Postepy Hig Med Dosw; 1973; 27(2):209-39. PubMed ID: 4787947
[No Abstract] [Full Text] [Related]
19. Action of m-tyrosine in experimental models: evidence for possible antiparkinsonian activity.
Ungerstedt U; Fuxe K; Goldstein M; Battista A; Ogawa M; Anagnoste B
Eur J Pharmacol; 1973 Feb; 21(2):230-7. PubMed ID: 4633120
[No Abstract] [Full Text] [Related]
20. Ontogenic variations in responses to L-DOPA and monoamine receptor-stimulating agents.
Kellogg C; Lundborg P
Psychopharmacologia; 1972; 23(2):187-200. PubMed ID: 5022609
[No Abstract] [Full Text] [Related]
[Next] [New Search]
